Baxter Expands Recall of Anticoagulant Sodium Citrate Solution to One Lot
FDA reports Baxter International Inc. is recalling one lot of Anticoagulant Sodium Citrate Solution due to potential fiberglass particulate matter.
4 reports on this incident · first at Aug 26, 2026, 8:45 a.m. ET
Earlier reports
Aug 26, 2026, 8:52 a.m. ET
FDA Reports Injuries in Baxter Anticoagulant Sodium Citrate Recall
The U.S. Food and Drug Administration (FDA) has reported that injuries or illnesses have now been reported in connection with the recall of one lot of Baxter Anticoagulant Sodium Citrate Solution USP, 250 mL VIAFLEX Plastic Container. The recall, initiated on August 25, 2026, was due to the potential presence of particulate matter identified as fiberglass in the solution. According to the FDA, the customer should immediately discontinue use of and return all affected units in accordance with their facility’s process.
Baxter International Inc. initiated the recall on August 25, 2026, affecting one lot distributed to one customer in the United States. The FDA states that administration of the solution containing particulate matter may lead to adverse health consequences, including local vein irritation, inflammatory or hypersensitivity reactions, and systemic embolization that could result in tissue or organ injury. Baxter has not received any reports of adverse events related to this issue, according to the FDA. The recall status is listed as ongoing.
Aug 26, 2026, 8:50 a.m. ET
FDA Closes Recall of Baxter Anticoagulant Sodium Citrate Lot
The U.S. Food and Drug Administration has closed the recall of one lot of Baxter's Anticoagulant Sodium Citrate Solution USP, 250 mL VIAFLEX Plastic Container, initiated August 25, 2026. The agency considers the recall carried out, according to the FDA.
The recall was prompted by the potential presence of particulate matter identified as fiberglass in the solution, which may cause adverse health consequences. Baxter has not received any reports of adverse events related to this issue.
The customer should immediately discontinue use of and return all affected units in accordance with their facility’s process.
Aug 26, 2026, 8:45 a.m. ETFirst report
Baxter Recalls One Lot of Anticoagulant Sodium Citrate Solution Due to Particulate Matter
Baxter International Inc. has issued a voluntary nationwide recall of one lot of Anticoagulant Sodium Citrate Solution USP, 250 mL VIAFLEX Plastic Container, according to the U.S. Food and Drug Administration (FDA). The recall was initiated on August 25, 2026, and is ongoing.
The recall was prompted by the potential presence of particulate matter identified as fiberglass in the solution. Administration of the product containing particulate matter may lead to adverse health consequences, including local vein irritation, inflammatory or hypersensitivity reactions, and systemic embolization that could result in tissue or organ injury, the FDA reported.
The product was distributed to one customer in the United States. Baxter has not received any reports of adverse events related to this issue, the FDA stated.
The FDA advises that the customer should immediately discontinue use of and return all affected units in accordance with their facility's process.
Was this report accurate and useful?
Sources
Revision history
- Version 126 Aug 2026, 13:22current
First published.
- Version 126 Aug 2026, 12:45current
First published.
- Version 126 Aug 2026, 12:52current
First published.
- Version 126 Aug 2026, 12:50current
First published.
How we work
This site models an investigative reporter rather than a wire desk. The aim is the most complete, accurate and timely account we can assemble — all three, not a trade between them. Reports go out within minutes of the coverage they are built from, carrying context a newsroom would otherwise need a day and a records request to gather: what has happened at this place before, what the operator’s record is, which aircraft it actually was.
Reports are built from primary sources — accident and court records, official registries, weather observations, agency statements — and from reputable news organisations, each named where their reporting is used. Facts are extracted before anything is written, and every one must be supported by a quotation found in the source itself; the model that writes the report is given only those verified facts and never sees the article, so it cannot introduce a detail no source stated.
Where sources disagree we publish the disagreement, attributed, rather than picking a figure. Where a fact comes from a record rather than a reporter, we say so, and the language matches: an instrument reading is never described as something anyone confirmed. Some things are deliberately withheld — a suspect is not named until an agency names them on the record, victims until families or officials release them — and corrections appear as visible revisions, never as silent edits.
None of that makes a report true. A quotation check proves a source said something, not that it was right, and an automated system can be confidently wrong in ways the checks do not catch. If something here is wrong, the feedback above is how it gets found. The full methodology, including what we refuse to publish.